Literature DB >> 8706773

Pharmacokinetics of dexamethasone in premature neonates.

R A Lugo1, M C Nahata, J A Menke, R E McClead.   

Abstract

OBJECTIVE: Dexamethasone is frequently used in premature neonates with bronchopulmonary dysplasia, however little is known about its disposition in this population.
METHODS: We evaluated the pharmacokinetics of dexamethasone in 9 premature neonates with a mean gestational age of 27.3 weeks and a postnatal age of 21.8 days.
RESULTS: There was a strong relationship between clearance (4.96 ml.min-1.kg-1) and gestational age ( r = 0.884). Pharmacokinetic parameters were grouped based on a gestational age of less than 27 weeks (Group I) and greater than 27 weeks (Group II). Mean clearance in group I and group II was 1.69 and 7,57 ml.min-1.kg-1, respectively. Mean distribution volume in group I and II was 1.26 and 2.19 l.kg-1, respectively. No significant relationships were noted between the disposition of dexamethasone and ventilator requirements or adverse effects.
CONCLUSION: The pharmacokinetics of dexamethasone in premature neonates was related to gestational age.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706773     DOI: 10.1007/BF00195934

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Collaborative Dexamethasone Trial Group.

Authors: 
Journal:  Pediatrics       Date:  1991-09       Impact factor: 7.124

2.  High-dose corticosteroids in severe acute asthma.

Authors:  M G Britton; J V Collins; D Brown; N P Fairhurst; R G Lambert
Journal:  Br Med J       Date:  1976-07-10

3.  A catabolic state in dexamethasone treatment of bronchopulmonary dysplasia.

Authors:  P D Macdonald; P Galea; L G Alroomi
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

Review 4.  The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.

Authors:  P C Ng
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

5.  Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.

Authors:  G B Avery; A B Fletcher; M Kaplan; D S Brudno
Journal:  Pediatrics       Date:  1985-01       Impact factor: 7.124

6.  A randomized, placebo-controlled trial of effects of dexamethasone on hypothalamic-pituitary-adrenal axis in preterm infants.

Authors:  D M Wilson; R B Baldwin; R L Ariagno
Journal:  J Pediatr       Date:  1988-10       Impact factor: 4.406

7.  Disposition of synethetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults.

Authors:  S E Tsuei; R G Moore; J J Ashley; W G McBride
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

8.  Dexamethasone increases plasma amino acid concentrations in bronchopulmonary dysplasia.

Authors:  A F Williams; M Jones
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

9.  A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids.

Authors:  G Hochhaus; R Hochhaus; G Werber; H Derendorf; H Möllmann
Journal:  Biomed Chromatogr       Date:  1992 Nov-Dec       Impact factor: 1.902

10.  Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia.

Authors:  M C Mammel; T P Green; D E Johnson; T R Thompson
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

View more
  8 in total

1.  Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants.

Authors:  Ann R Stark; Waldemar A Carlo; Betty R Vohr; Lu Ann Papile; Shampa Saha; Charles R Bauer; William Oh; Seetha Shankaran; Jon E Tyson; Linda L Wright; W Kenneth Poole; Abhik Das; Barbara J Stoll; Avroy A Fanaroff; Sheldon B Korones; Richard A Ehrenkranz; David K Stevenson; Myriam Peralta-Carcelen; Deanne E Wilson-Costello; Henrietta S Bada; Roy J Heyne; Yvette R Johnson; Kimberly Gronsman Lee; Jean J Steichen
Journal:  J Pediatr       Date:  2013-08-27       Impact factor: 4.406

2.  Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.

Authors: 
Journal:  Paediatr Child Health       Date:  2002-01       Impact factor: 2.253

3.  In vitro effect of dexamethasone phosphate on hematopoietic progenitor cells in preterm infants.

Authors:  P Papoff; R D Christensen; J Harcum; Y Li
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

4.  Transcriptional control of cytokine release from monocytes of the newborn: effects of endogenous and exogenous interleukin-10 versus dexamethasone.

Authors:  Lina A Chusid; Lucy Pereira-Argenziano; Veronika Miskolci; Ivana Vancurova; Dennis Davidson
Journal:  Neonatology       Date:  2009-08-28       Impact factor: 4.035

5.  Differential effect of exogenous interleukin-10 versus glucocorticoids on gene expression and pro-inflammatory cytokine release by polymorphonuclear leukocytes and monocytes of the newly born.

Authors:  Dennis Davidson; Hardik Patel; Ana C Degoy; Irina Gershkovich; Ivana Vancurova; Veronika Miskolci
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

6.  Interleukin-10 versus dexamethasone: effects on polymorphonuclear leukocyte functions of the newborn.

Authors:  Brett V Citarella; Veronika Miskolci; Ivana Vancurova; Dennis Davidson
Journal:  Pediatr Res       Date:  2009-04       Impact factor: 3.756

7.  Anti-inflammatory actions of endogenous and exogenous interleukin-10 versus glucocorticoids on macrophage functions of the newly born.

Authors:  K Kasat; H Patel; O Predtechenska; I Vancurova; D Davidson
Journal:  J Perinatol       Date:  2014-02-13       Impact factor: 2.521

8.  Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro.

Authors:  Esther M Speer; David J Dowling; Jianjin Xu; Lukasz S Ozog; Jaime A Mathew; Avinash Chander; Donglei Yin; Ofer Levy
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.